Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Raymond James analyst Andrew Cooper upgrades Azenta (NASDAQ:AZTA) from Market Perform to Outperform and announces $35 price ...
Evercore ISI Group analyst Vijay Kumar maintains Azenta (NASDAQ:AZTA) with a In-Line and lowers the price target from $35 to...
Azenta (NASDAQ:AZTA) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.13 by 43.94...
Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Ca...
Evercore ISI Group analyst Vijay Kumar maintains Azenta (NASDAQ:AZTA) with a In-Line and raises the price target from $29 to...
Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patie...
Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and lowers the price target from $59 to $40.
